Drugs / 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06675032 | Apr 2024 → May 2025 overdue | pneumococcal infection | Shanghai Reinovax Biologics Co.,LTD | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05092386 | Jan 2023 → May 2024 | pneumococcal infection | Sinovac Life Sciences Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02736240 | Apr 2016 → Dec 2017 | pneumococcal infection | Walvax Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07591181 | May 2026 → Dec 2027 expected | pneumococcal infection | Beijing Center for Disease Control and Prevention | Not yet recruiting | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 1 | NCT05602480 Comparator | Nov 2022 → Jun 2024 | pneumococcal infection | Wuhan BravoVax Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04100772 Comparator | May 2020 → Jun 2021 | pneumococcal infection | CanSino Biologics Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT07600983 Comparator | May → Nov 2026 expected | pneumococcal infection | CanSino Biologics Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04841369 Comparator | Apr 2021 → Mar 2022 | pneumococcal infection | CanSino Biologics Inc. | Completed | No outcome recorded |
| — | NCT05939219 Comparator | Jul 2023 → Jan 2025 | — | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Unknown | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-06-20 | CanSino Biologics Inc. | CanSinoBIO Obtained NDA Approval for its 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine iPneucia® cansinotech.com ↗ |
| 2019-01-02 | CanSino Biologics Inc. | CanSinoBio Submitted Clinical Trial Application of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）to NMPA cansinotech.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 13-valent pneumococcal polysaccharide conjugate vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02736240 ↗ |
| Known as | PCV13 | “13-valent pneumococcal polysaccharide conjugate vaccine (referred to as PCV13)” NCT07600983 ↗1“investigational 13-valent pneumococcal conjugate vaccine (PCV13)” PMID 27798013 ↗ Oct 2016 |
| Known as | PCV13 vaccine | “1 dose ( 0.5ml) of PCV13 vaccine” NCT07600983 ↗ |
| Modality | Vaccine | “13-valent pneumococcal conjugate vaccine (PCV13)” PMID 27798013 ↗ Oct 2016 |
| Route | Intramuscular | “0.5mL,Intramuscular” NCT04841369 ↗ |